SABR PRIMER - Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors

What this study is about

The study is being done to determine if stereotactic ablative radiotherapy (SABR) can control tumour growth for patients with metastatic breast cancer. Secondary objectives will be overall survival, progression-free survival and time to switch of next line of systemic therapy. Radiation-related adverse events will be assess, with a specific focus on dermatitis, lymphedema and brachial plexopathy. The exploratory objective is to correlate toxicities and outcomes with peripheral blood biomarkers and circulating tumor DNA to potentially help predict responses in future patients receiving combined therapy.

Who can join (things the study team will check)

✅ You may be able to join if…

• Pathologically confirmed AJCC 7th/8th edition Stage IV invasive ductal carcinoma or invasive lobular carcinoma of the breast.
• Measurable disease in the breast, suitable to receive radiotherapy.
• Receiving or planned to receive systemic therapy. a. The following should be held for the duration of treatment: cytotoxic chemotherapy, CDK4/6 inhibitors, T-DXd
• Patients are allowed to have SABR for oligometastatic disease as clinically indicated
• Age 18 or older
• ECOG Performance Status 0-2
• Life expectancy greater than 6 months
• Able and willing to provide informed consent
• Able to complete patient reported outcome questionnaires

🚫 You may not be able to join if…

• Contraindications to radiotherapy, including a history of SLE, systemic scleroderma, IPF, ataxia telangiectasia, pregnancy
• Previous history of locoregional radiotherapy to the ipsilateral breast

Where this trial is running

• BC Cancer - Vancouver, Vancouver, British Columbia, Canada

Who to contact

Sandy Chang · 6048776000 · sandy.chang@bccancer.bc.ca

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06937281.